Abstract
On March 4, 2025, the World Obesity Atlas 2025 was published by the World Obesity Federation and reported that the total number of adults living with obesity is now projected to increase by more than 115% between 2010 and 2030 (from 524 million to 1.13 billion). On May 9, 2025, an analysis of the global market for weight-loss medications identified the exponential growth of obesity drugs, with a previous market projection for 2035 of $105 billion, is now revised to $150 billion. Several emerging oral compounds for weight reduction are currently under clinical evaluation, including oral glucagon-like peptide 1 (GLP-1) receptor agonists. The US Food and Drug Administration (FDA) has recently accepted a new drug application for oral semaglutide, which, if approved, will be the first oral drug authorized for long-term weight management. However, because efficacy and safety data have mainly come from clinical trials, long-term effects on weight loss, treatment adherence, and side effects require long-term and real-world evaluation. Increasing demands and drug costs also drive the production of compounded versions (copycat drugs), which have escalated for GLP-1 receptor agonists, with products without quality and safety evaluation. This editorial aims to provide an update on the global challenges of increasing rates of obesity and the demands for therapeutic approaches to weight loss, including GLP-1 receptor agonists.